Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment.
Onkar S, Cui J, Zou J, Cardello C, Cillo AR, Uddin MR, Sagan A, Joy M, Osmanbeyoglu HU, Pogue-Geile KL, McAuliffe PF, Lucas PC, Tseng GC, Lee AV, Bruno TC, Oesterreich S, Vignali DAA. Onkar S, et al. Among authors: lucas pc. Nat Cancer. 2023 Apr;4(4):516-534. doi: 10.1038/s43018-023-00527-w. Epub 2023 Mar 16. Nat Cancer. 2023. PMID: 36927792
Publisher Correction: Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment.
Onkar S, Cui J, Zou J, Cardello C, Cillo AR, Uddin MR, Sagan A, Joy M, Osmanbeyoglu HU, Pogue-Geile KL, McAuliffe PF, Lucas PC, Tseng GC, Lee AV, Bruno TC, Oesterreich S, Vignali DAA. Onkar S, et al. Among authors: lucas pc. Nat Cancer. 2023 Apr;4(4):582. doi: 10.1038/s43018-023-00549-4. Nat Cancer. 2023. PMID: 37012402 No abstract available.
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
Fernandez-Martinez A, Rediti M, Tang G, Pascual T, Hoadley KA, Venet D, Rashid NU, Spears PA, Islam MN, El-Abed S, Bliss J, Lambertini M, Di Cosimo S, Huobe J, Goerlitz D, Hu R, Lucas PC, Swain SM, Sotiriou C, Perou CM, Carey LA. Fernandez-Martinez A, et al. Among authors: lucas pc. JAMA Oncol. 2024 May 1;10(5):603-611. doi: 10.1001/jamaoncol.2023.7304. JAMA Oncol. 2024. PMID: 38546612 Free PMC article.
Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Jacobs SA, Wang Y, Abraham J, Feng H, Montero AJ, Lipchik C, Finnigan M, Jankowitz RC, Salkeni MA, Maley SK, Puhalla SL, Piette F, Quinn K, Chang K, Nagy RJ, Allegra CJ, Vehec K, Wolmark N, Lucas PC, Srinivasan A, Pogue-Geile KL. Jacobs SA, et al. Among authors: lucas pc. Breast Cancer Res. 2024 May 24;26(1):83. doi: 10.1186/s13058-024-01833-6. Breast Cancer Res. 2024. PMID: 38790033 Free PMC article. No abstract available.
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Jacobs SA, Wang Y, Abraham J, Feng H, Montero AJ, Lipchik C, Finnigan M, Jankowitz RC, Salkeni MA, Maley SK, Puhalla SL, Piette F, Quinn K, Chang K, Nagy RJ, Allegra CJ, Vehec K, Wolmark N, Lucas PC, Srinivasan A, Pogue-Geile KL. Jacobs SA, et al. Among authors: lucas pc. Breast Cancer Res. 2024 Apr 22;26(1):69. doi: 10.1186/s13058-024-01823-8. Breast Cancer Res. 2024. PMID: 38650031 Free PMC article. Clinical Trial.
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial.
Mamounas EP, Bandos H, Rastogi P, Zhang Y, Treuner K, Lucas PC, Geyer CE Jr, Fehrenbacher L, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil S, Paik S, Swain SM, Sgroi DC, Schnabel CA, Wolmark N. Mamounas EP, et al. Among authors: lucas pc. Clin Cancer Res. 2024 May 1;30(9):1984-1991. doi: 10.1158/1078-0432.CCR-23-1977. Clin Cancer Res. 2024. PMID: 38376912 Free PMC article. Clinical Trial.
127 results